An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity

Journal of Interferon and Cytokine Research

Volumn 18, Issue 8, 1998, Pages 597-607

  Penichet, Manuel L ^a   Harvill, Eric T ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G3; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; DOSE RESPONSE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCINTILLATION CAMERA;

ANIMALIA; MURINAE;

EID: 0031870775     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.597     Document Type: Article

References (74)

1. YRON, I., WOOD, T., JR., SPIESS, P.J., and ROSENBERG, S.A. (1980). In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immunol. 125, 238-245.
2. LOTZE, M.T., GRIMM, E.A., MAZUMDER, A., STRAUSSER, J.L., and ROSENBERG, S.A. (1981). Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 41, 4420-4425.
3. GRIMM, E.A., MAZUMDER, A., ZHANG, H.Z., and ROSENBERG, S.A. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
4. HANK, J.A., ROBINSON, R.R., SURFUS, J., MUELLER, B.M., REISFELD, R.A., CHEUNG, N.K., and SONDEL, P.M. (1990). Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 50, 5234-5239.
5. TALMADGE, J.E., PHILLIPS, H., SCHINDLER, J., TRIBBLE, H., and PENNINGTON, R. (1987). Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 47, 5725-5732.
6. MAAS, R.A., DULLENS, H.F., and DEN OTTER, W. (1993). Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141-148.
7. RUBIN, J.T., ELWOOD, L.J., ROSENBERG, S.A., and LOTZE, M.T. (1989). Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 49, 7086-7092.
8. WHITTINGTON, R., and FAULDS, D. (1993). Interteukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46, 446-514.
9. ROSENBERG, S.A., YANNELLI, J.R., YANG, J.C., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., WEBER, J.S., PARKINSON, D.R., SEIPP, C.A., EINHORN, J.H., and WHITE, D.E. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166.
10. LOTZE, M.T., MATORY, Y.L., ETTINGHAUSEN, S.E., RAYNER, A.A., SHARROW, S.O., SEIPP, C.A., CUSTER, M.C., and ROSENBERG, S.A. (1985). In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865-2875.
11. SIEGEL, J.P., and PURI, R.K. (1991). Interleukin-2 toxicity, J. Clin. Oncol. 9, 694-704.
12. HARADA, Y., and YAHARA, I. (1993). Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int. Rev. Exp. Pathol. 34,(Pt. A), 37-55.
13. PONCE, P., CRUZ, J., TRAVASSOS, J., MOREIRA, P., OLIVEIRA, J., MELO, G.E., and GOUVEIA, J. (1993). Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron 64, 114-118.
14. DONOHUE, J.H., and ROSENBERG, S.A. (1983). The fate of interleukin-2 after in vivo administration. J. Immunol. 130, 2203-2208.
15. PIZZA, G., SEVERINI, G., MENNITI, D., DE VINCI, C., and CORRADO, F. (1984). Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer 34, 359-367.
16. FORNI, G., MUSSO, T., SANTONI, A., and GIOVARELLI, M. (1987). Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth. Prog. Clin. Biol. Res. 244, 105-114.
17. CORTESINA, G., DE STEFANI, A., GIOVARELLI, M., BARIOGLIO, M.G., CAVALLO, G.P., JEMMA, C., and FORNI, G. (1988). Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62, 2482-2485.
18. RUTTEN, V.P., KLEIN, W.R., DE JONG, W.A., MISDORP, W., DEN OTTER, W., STEERENBERG, P.A., DE JONG, W.U., and RUITENBERG, E.J. (1989). Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol. Immunother. 30, 165-169.
19. MAAS, R.A., DULLENS, H.F., DE JONG, W.H., and DEN OTTER, W. (1989). Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res. 49, 7037-7040.
20. MAAS, R.A., VAN WEERING, D.H., DULLENS, H.F., and DEN OTTER, W. (1991). Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol. Immunother. 33, 389-394.
21. SU, N., OJEIFO, J.O., MACPHERSON, A., and ZWIEBEL, J.A. (1994). Breast cancer gene therapy: transgenic immunotherapy. Breast Cancer Res. Treat. 31, 349-356.
22. SCHMIDT, W., SCHWEIGHOFFER, T., HERBST, E., MAASS, G., BERGER, M., SCHILCHER, F., SCHAFFNER, G., and BIRNSTIEL, M.L. (1995). Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-4714.
23. ZATLOUKAL, K., SCHNEEBERGER, A., BERGER, M., SCHMIDT, W., KOSZIK, F., KUTIL, R., COTTEN, M., WAGNER, E., BUSCHLE, M., MAASS, G., et al. (1995). Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine. Assessment of critical cellular and molecular parameters. J. Immunol. 154, 3406-3419.
24. MAASS, G., SCHMIDT, W., BERGER, M., SCHILCHER, F., KOSZIK, F., SCHNEEBERGER, A., STINGL, G., BIRNSTIEL, M.L., and SCHWEIGHOFFER, T. (1995). Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92, 5540-5544.
25. DRANOFF, G., and MULLIGAN, R.C. (1995). Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454.
26. RIETHMULLER, G., SCHNEIDER, G.E., and JOHNSON, J.P. (1993). Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 5, 732-739.
27. GILLIES, S.D., YOUNG, D., LO, K.M., and ROBERTS, S. (1993). Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug. Chem. 4, 230-235.
28. TSOMIDES, T.J., and EISEN, H.N. (1994). T-cell antigens in cancer. Proc. Natl. Acad. Sci. USA 91, 3487-3489.
29. BERINSTEIN, N., and LEVY, R. (1987). Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J. Immunol. 139, 971-976.
30. BERINSTEIN, N., STARNES, C.O., and LEVY, R. (1988). Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J. Immunol. 140, 2839-2845.
31. LEBERTHON, B., KHAWLI, L.A., ALAUDDIN, M., MILLER, G.K., CHARAK, B.S., MAZUMDER, A., and EPSTEIN, A.L. (1991). Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 51, 2694-2698.
32. HU, P., HORNICK, J.L., GLASKY, M.S., YUN, A., MILKIE, M.N., KHAWLI, L.A., ANDERSON, P.M., and EPSTEIN, A.L. (1996). A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. 56, 4998-5004.
33. HANK, J.A., SURFUS, J., GAN, J., CHEW, T.L., HONG, R., TANS, K., REISFELD, R., SEEGER, R.C., REYNOLDS, C.P., BAUER, M., et al. (1994). Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J. Immunother. 15, 29-37.
34. FELL, H.P., GAYLE, M.A., GROSMAIRE, L., and LEDBETTER, J.A. (1991). Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL-2. J. Immunol. 146, 2446-2452.
35. GILLIES, S.D., REILLY, E.B., LO, K.M., and REISFELD, R.A. (1992). Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89, 1428-1432.
36. NICOLET, C.M., BURKHOLDER, J.K., GAN, J., GULP, J., KASHMIRI, S.V., SCHLOM, J., YANG, N.S., and SONDEL, P.M. (1995). Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. Cancer Gene Ther. 2, 161-170.
37. BOLETI, E., DEONARAIN, M.P., SPOONER, R.A., SMITH, A.J., EPENETOS, A.A., and GEORGE, A.J. (1995). Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein. Ann. Oncol. 6, 945-947.
38. BEI, R., SCHLOM, J., and KASHMIRI, S.V. (1995). Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. J. Immunol. Methods 186, 245-255.
39. HARVILL, E.T., and MORRISON, S.L. (1995). An IgG3-IL-2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1, 95-105.
40. HARVILL, E.T., FLEMING, J.M., and MORRISON, S.L. (1996). In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. 157, 3165-3170.
41. HARVILL, E.T., and MORRISON, S.L. (1996). An IgG3-IL-2 fusion protein has higher affinity than hiIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. Mol. Immunol. 33, 1007-1014.
42. SABZEVARI, H., GILLIES, S.D., MUELLER, B.M., PANCOOK, J.D., and REISFELD, R.A. (1994). A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA 91, 9626-9630.
43. PANCOOK, J.D., BECKER, J.C., GILLIES, S.D., and REISFELD, R.A. (1996). Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol. Immunother. 42, 88-92.
44. BECKER, J.C., VARKI, N., GILLIES, S.D., FURUKAWA, K., and REISFELD, R.A. (1996). Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98, 2801-2804.
45. BECKER, J.C., VARKI, N., GILLIES, S.D., FURUKAWA, K., and REISFELD, R.A. (1996). An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA 93, 7826-7831.
46. BECKER, J.C., PANCOOK, J.D., GILLIES, S.D., FURUKAWA, K., and REISFELD, R.A. (1996). T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183, 2361-2366.
47. BECKER, J.C., PANCOOK, J.D., GILLIES, S.D., MENDELSOHN, J., and REISFELD, R.A. (1996). Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA 93, 2702-2707.
48. MALONEY, D.G., KAMINSKI, M.S., BUROWSKI, D., HAIMOVICH, I., and LEVY, R. (1985). Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4, 191-209.
49. KAMINSKI, M.S., KITAMURA, K., MALONEY, D.G., CAMPBELL, M.J., and LEVY, R. (1986). Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136, 1123-1130.
50. BERGMAN, Y., HAIMOVICH, J., and MELCHERS, F. (1997). An IgM-producing tumor with biochemical characteristics of a small B lymphocyte. Eur. J. Immunol. 7, 574-579.
51. BERGMAN, Y., and HAIMOVICH, J. (1977). Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur. J. Immunol. 7, 413-417.
52. PEREK, Y., HURWITZ, E., BUROWSKI, D., and HAIMOVICH, J. (1983). Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM. J. Immunol. 131, 1600-1603.
53. SHIN, S.U., and MORRISON, S.L. (1989). Production and properties of chimeric antibody molecules. Methods Enzymol. 178, 459-476.
54. EPENETOS, A.A., SNOOK, D., DURBIN, H., JOHNSON, P.M., and TAYLOR, P.J. (1986). Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46, 3183-3191.
55. JAIN, R.K. (1990). Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, S814-S819.
56. MURRAY, J.L. (1992). Factors for improving monoclonal-antibody targeting. Diagn. Oncol. 2, 234-241.
57. GOLDENBERG, D.M. (1993). Monoclonal antibodies in cancer detection and therapy. Am. J. Med. 94, 297-312.
58. KEMSHEAD, J.T., and HOPKINS, K. (1993). Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J. R. Soc. Med. 86, 219-224.
59. KOSMAS, C., KALOFONOS, H.P., and EPENETOS, A.A. (1990). Radiolabelled monoclonal antibodies in tumour diagnosis and therapy. Dev. Biol. Stand. 71, 93-102.
60. 111Inlabeled T101 monoclonal antibody. N. Engl. J. Med. 315, 673-680.
61. GOODWIN, D.A. (1987). Pharmacokinetics and antibodies. J. Nucl. Med. 28, 1358-1362.
62. DYKES, P.W., BRADWELL, A.R., CHAPMAN, C.E., and VAUGHAN, A.T. (1987). Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat. Rev. 14, 87-106.
63. GOLDENBERG, D.M. (1988). Targeting of cancer with radiolabeled antibodies. Prospects for imaging and therapy. Arch. Pathol. Lab. Med. 112, 580-587.
64. BERNSEN, M.R., DULLENS, H.F., DEN OTTER, W., and HEINTZ, P.M. (1995). Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2. J. Interferon Cytokine Res. 15, 641-645.
65. MATTIJSSEN, V., BALEMANS, L.T.M., STEERENBERG, P.A., and DEMULDER, P.H.M. (1992). Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors. Int. J. Cancer 51, 812-817.
66. ZIMMERMAN, R.J., AUKERMAN, S.L., KATRE, N.V., WINKELHAKE, J.L., and YOUNG, J.D. (1989). Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models. Cancer Res. 49, 6521-6528.
67. KATRE, N.V., KNAUF, M.J., and LAIRD, W.J. (1987). Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA 84, 1487-1491.
68. RUSSELL, S.J. (1990). Lymphokine gene therapy for cancer [see Comments]. Immunol. Today 11, 196-200.
69. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
70. VISSEREN, M.J., KOOT, M., VAN DER VOORT, E.I., GRAVESTEIN, L.A., SCHOENMAKERS, H.J., KAST, W.M., ZIJLSTRA, M., and MELIEF, C.J. (1994). Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. Immunother. Emphasis Tumor Immunol. 15, 119-128.
71. MIZOGUCHI, H., O'SHEA, J.J., LONGO, D.L., LOEFFLER, C.M., McVICAR, D.W., and OCHOA, A.C. (1992). Alterations is signal transduction molecules in T lymphocytes from tumor-bearing mice [see Comments]. Science 258, 1795-1798.
72. KERÉKGYART, C., VIRAG, L., TANK, L., CHIHARA, G., and FACHET, J. (1996). Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. Int. J. Immunopharmacol. 128, 347-353.
73. BOACH-OLSZEWSKA, Z., ZACZYNSKA, E., BRONIAREK, E., and INGLOT, A.D. (1993). Production of cytokines by mouse peritoneal cells treated with Topa Torf Preparation (TTP): dependence on age and strain of mice. Arch. Immunol. Ther. Exp. (Warsz.) 41, 81-85.
74. RATAJCZAK, H.V., THOMAS, P.T., SOTHERN, R.B., VOLLMUTH, T., and HECK, J.D. (1993). Evidence for genetic basis of seasonal differences in antibody formation between two mouse strains. Chronobiol. Int. 10, 383-394.